| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
18,864 |
17,518 |
$967K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,940 |
16,876 |
$657K |
| S8301 |
Infection control supplies, not otherwise specified |
25,042 |
22,854 |
$384K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,812 |
3,719 |
$295K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
20,840 |
9,966 |
$205K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,253 |
2,184 |
$111K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,437 |
1,412 |
$107K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,169 |
1,148 |
$98K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
10,151 |
9,627 |
$86K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
520 |
504 |
$69K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,088 |
2,027 |
$60K |
| 99429 |
|
1,763 |
1,714 |
$56K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
327 |
320 |
$44K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
376 |
372 |
$34K |
| 90461 |
|
3,420 |
2,913 |
$19K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
586 |
564 |
$15K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
510 |
492 |
$7K |
| 0071A |
|
148 |
145 |
$6K |
| 0072A |
|
62 |
62 |
$2K |
| 0082A |
|
52 |
51 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
78 |
62 |
$1K |
| 87807 |
|
104 |
96 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
66 |
62 |
$901.53 |
| 96160 |
|
320 |
316 |
$671.47 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
27 |
27 |
$669.58 |
| 0083A |
|
14 |
12 |
$480.00 |
| 0081A |
|
12 |
12 |
$408.00 |
| 83655 |
|
27 |
27 |
$305.10 |
| 90686 |
|
3,500 |
3,337 |
$72.61 |
| 81002 |
|
13 |
13 |
$37.96 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
25 |
24 |
$1.15 |
| 90619 |
|
29 |
25 |
$0.12 |
| 90671 |
|
160 |
153 |
$0.00 |
| 90670 |
|
773 |
753 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
398 |
358 |
$0.00 |
| 90633 |
|
12 |
12 |
$0.00 |
| 90698 |
|
263 |
261 |
$0.00 |
| 90680 |
|
173 |
171 |
$0.00 |
| 90656 |
|
199 |
197 |
$0.00 |
| 90620 |
|
12 |
12 |
$0.00 |
| 90651 |
|
14 |
14 |
$0.00 |